BCR and B-cell chronic lymphocytic leukemia: Venetoclax is approved for relapsed/refractory CLL with TP53 mutation/deletion, and for CLL patients relapsing during treatment with BCR inhibitors, either alone [50] or preferably, if the patients’ fitness status permits, in combination with rituximab [7,51].